• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Notice to attend the Extra General Meeting of Olink Holding AB (publ)

    7/11/24 4:05:45 PM ET
    $OLK
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $OLK alert in real time by email

    This is a translation of the Swedish original. In case of any discrepancies between this translation and the Swedish original, the latter shall prevail.

    UPPSALA, Sweden, July 11, 2024 (GLOBE NEWSWIRE) -- The shareholders of Olink Holding AB (publ) (the "Company"), reg. no. 559189-7755, are hereby given notice to attend the Extra General Meeting to be held at 4:00 p.m. CEST on Tuesday 6 August 2024, in the Company's facilities at Salagatan 16F, Uppsala. Registration for the meeting commences at 3:30 p.m. CEST.

    NOTICE OF PARTICIPATION

    Shareholders who wish to attend in the proceedings of the Extra General Meeting must:

    • be entered in the share register kept on behalf of the Company by Euroclear Sweden AB, as of Monday 29 July 2024; and
    • notify the Company's head office at Olink Holding AB (publ), Extra General Meeting 2024, Salagatan 16F, SE-753 30 Uppsala, Sweden or by telephone +46 (0)18 444 39 70 or via e-mail to [email protected] no later than Wednesday 31 July 2024. The notification must contain the shareholder's name, social security number (or corporate registration number, as applicable), address, telephone number, the number of shares represented as well as any attending counsel, maximum two.

    Personal data obtained from the share register kept by Euroclear Sweden AB, notices and attendance at the meeting and information on representatives, proxies and assistants will be used for registration, preparation of the voting list for the meeting and, where appropriate, the minutes of the meeting. Personal data is handled in accordance with the Data Protection Regulation (European Parliament and Council Regulation (EU) 2016/679). For full information regarding the Company's handling of personal data, please refer to our privacy policy: https://www.olink.com/about-us/integrity-policy/.

    To be entitled to participate in the General Meeting a shareholder whose shares are registered in the name of a nominee must, in addition to providing notification of participation at the General Meeting, register its shares in its own name so that the shareholder is recorded in the share register on Monday 29 July 2024. Such registration may be temporary (so-called voting right registration) and is requested with the nominee in accordance with the nominee's procedures and such time in advance as the nominee determines. Voting right registrations completed not later than Wednesday 31 July 2024 are taken into account when preparing the share register.

    The Company intends to enable shareholders to participate electronically via link. It should however be noted that such a procedure presupposes that the General Meeting first approves that pre-registered persons participate via link. In the case of participation via link, there is no support for managing the voting register, which means that if participants via link actively want to influence the Extra General Meeting's decisions, this must be done by the shareholder issuing a power of attorney to a person who physically participates in the Extra General Meeting. If there are registered persons on Wednesday 31 July 2024 that wish to participate via link, the Company will send out an invitation with instructions on how to join the Extra General Meeting electronically.

    OPPORTUNITY FOR SHAREHOLDERS TO EXERCISE VOTING RIGHTS THROUGH PROXY

    Shareholders who do not wish to attend the meeting in person may authorize a proxy to exercise their voting rights. A power of attorney may be issued to the Chairman of the Meeting or another person attending the Extra General Meeting. If the power of attorney is issued to the Chairman of the Meeting, the power of attorney must be combined with a voting instruction so that the Chairman of the Meeting knows how to vote under the various decision points. If the power of attorney is not combined with a voting instruction, the Chairman will not be able to represent the shareholder at the meeting. In other cases, the power of attorney should also be combined with a voting instruction. If participation will be by proxy, the shareholder shall issue a written, signed and dated power of attorney together with any documents verifying authority. Proxies for legal entities must also be accompanied by a certificate of incorporation or equivalent document verifying authority. A copy of the power of attorney, the voting instruction and any certificate of incorporation should, well in advance of the meeting, be sent to the Company at the above address. The original power of attorney shall also be presented at the meeting, as applicable. The Company provides the shareholders with proxy forms as well as blank voting instructions, which can be obtained at the Company's head office or on the Company's website www.investors.olink.com on Tuesday 16 July 2024 at the latest.

    Note that the possibility of having a proxy exercise the shareholders' voting rights at the Extra General Meeting presupposes that the shareholder has made a notification of participation and is included in the share register in accordance with what is stated above under the heading "Notice of participation". It is thus not sufficient to simply submit a power of attorney.

    PROPOSED AGENDA

    1. Opening of the Meeting.
    2. Election of Chairman to preside over the Meeting.
    3. Preparation and approval of voting register.
    4. Approval of the agenda proposed by the Board.
    5. Election of one or two persons to approve the Minutes.
    6. Determination of whether the Meeting has been properly convened.
    7. Determination of the number of Board members.
    8. Determination of fees for the Board of Directors.
    9. Election of Board members and Chairman of the Board of Directors.
    10. Closing of the Meeting.

    PROPOSAL BY THE BOARD OF DIRECTORS WITH RESPECT TO RESOLUTION UNDER ITEM 2

    Election of chairman at the meeting

    The Chairman of the Board, Jon Hindar, is proposed as Chairman to preside over the Meeting.

    PROPOSALS WITH RESPECT TO RESOLUTIONS UNDER ITEM 7-9 OF THE AGENDA

    Determination of the number of board members, Determination of fees for the Board of Directors, Election of board members and Chairman of the Board of Directors

    It is proposed that the Board of Directors shall consist of three (3) Directors without deputies.

    It is proposed that no renumeration shall be paid to the Board of Directors.

    It is proposed that the Extra General Meeting resolves to elect Anthony Smith, Bram Monster and Michel Verhoosel as board members. Further, it is proposed to elect Anthony Smith as Chairman of the Board.

    SHARES AND VOTES

    The Company has issued a total of 124,739,269 shares. The total number of votes is 124,739,269. This information relates to the conditions at the time of issuing this notice.

    SHAREHOLDERS' RIGHT TO REQUEST INFORMATION

    Pursuant to Chapter 7, sections 32 and 57 of the Swedish Companies Act (Sw. aktiebolagslagen), the Board of Directors and the CEO are under a duty to, if any shareholder so requests and the Board of Directors deems that it can be made without material damage to the Company, provide information at the Extra General Meeting, regarding circumstances which may affect the assessment of a matter on the agenda. The duty to provide information also includes the Company's relationship with other group companies, the consolidated accounts and such circumstances regarding subsidiaries which are set out in the preceding sentence.

    DOCUMENTATION

    Proxy form and other documents that shall be available in accordance with the Swedish Companies Act will be available at the Company no later than Tuesday 16 July 2024 and will be sent to shareholders who so request and provide their postal address. These documents will also be available on the Company's website as from the same date.

    Uppsala in July 2024

    The Board of Directors

    Olink Holding AB (publ)

    IR contact

    David Deuchler, CFA

    Gilmartin Group

    [email protected]

    Media contact

    Michael B. Gonzales

    VP Global Marketing

    Mobile: +1 415 308 6467

    [email protected]



    Primary Logo

    Get the next $OLK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OLK

    DatePrice TargetRatingAnalyst
    1/5/2023$27.00Sector Outperform
    Scotiabank
    12/14/2022$28.00Buy
    Canaccord Genuity
    2/14/2022$33.00 → $32.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $OLK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Notice to attend the Extra General Meeting of Olink Holding AB (publ)

      This is a translation of the Swedish original. In case of any discrepancies between this translation and the Swedish original, the latter shall prevail. UPPSALA, Sweden, July 11, 2024 (GLOBE NEWSWIRE) -- The shareholders of Olink Holding AB (publ) (the "Company"), reg. no. 559189-7755, are hereby given notice to attend the Extra General Meeting to be held at 4:00 p.m. CEST on Tuesday 6 August 2024, in the Company's facilities at Salagatan 16F, Uppsala. Registration for the meeting commences at 3:30 p.m. CEST. NOTICE OF PARTICIPATION Shareholders who wish to attend in the proceedings of the Extra General Meeting must: be entered in the share register kept on behalf of the Company by Eur

      7/11/24 4:05:45 PM ET
      $OLK
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Thermo Fisher Scientific Completes Acquisition of Olink, Announces Commencement of Subsequent Offering Period

      Subsequent Offering Period Scheduled to Expire at 5:00 p.m., New York Time, on July 16, 2024 Thermo Fisher Scientific Inc. (NYSE:TMO) ("Thermo Fisher"), the world leader in serving science, today announced that it has completed its acquisition of Olink Holding AB (publ) ("Olink") (NASDAQ:OLK), a leading provider of next-generation proteomics solutions. The transaction values Olink at approximately $3.1 billion, net of $96 million of acquired cash. Olink will become part of Thermo Fisher's Life Sciences Solutions segment. "We are excited to welcome Olink colleagues to Thermo Fisher," said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher. "Protein research

      7/10/24 8:00:00 AM ET
      $OLK
      $TMO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Industrial Machinery/Components
    • Olink Announces Receipt of CMA Clearance for Proposed Acquisition by Thermo Fisher

      UPPSALA, Sweden, July 08, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) ("Olink") (NASDAQ:OLK) today announced that the UK Competition and Markets Authority (the "CMA") has unconditionally approved the previously announced tender offer (the "Offer") by Orion Acquisition AB (the "Buyer"), a wholly owned subsidiary of Thermo Fisher Scientific Inc. (NYSE:TMO) ("Thermo Fisher" or "Parent"), for all outstanding Common Shares and American Depositary Shares (together, the "Shares") of Olink for $26.00 per Share. The Offer is being made pursuant to the Purchase Agreement, dated as of October 17, 2023, by and between Thermo Fisher and Olink. As a result of the CMA approval, Olink and Thermo Fis

      7/8/24 7:37:45 AM ET
      $OLK
      $TMO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Industrial Machinery/Components

    $OLK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Scotiabank initiated coverage on Olink Holding with a new price target

      Scotiabank initiated coverage of Olink Holding with a rating of Sector Outperform and set a new price target of $27.00

      1/5/23 7:46:07 AM ET
      $OLK
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Canaccord Genuity initiated coverage on Olink Holding with a new price target

      Canaccord Genuity initiated coverage of Olink Holding with a rating of Buy and set a new price target of $28.00

      12/14/22 8:56:12 AM ET
      $OLK
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Morgan Stanley reiterated coverage on Olink Holding with a new price target

      Morgan Stanley reiterated coverage of Olink Holding with a rating of Equal-Weight and set a new price target of $32.00 from $33.00 previously

      2/14/22 8:24:48 AM ET
      $OLK
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $OLK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Olink Holding AB (Amendment)

      SC 13G/A - Olink Holding AB (publ) (0001835539) (Subject)

      2/14/24 10:03:04 AM ET
      $OLK
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Olink Holding AB

      SC 13G - Olink Holding AB (publ) (0001835539) (Subject)

      2/9/24 7:59:50 AM ET
      $OLK
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Olink Holding AB (Amendment)

      SC 13G/A - Olink Holding AB (publ) (0001835539) (Subject)

      11/13/23 9:02:39 AM ET
      $OLK
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $OLK
    Financials

    Live finance-specific insights

    See more
    • Olink reports first quarter 2024 financial results

      UPPSALA, Sweden, May 13, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) ("Olink") (NASDAQ:OLK) today announced its unaudited financial results for the first quarter ended March 31, 2024. Highlights First quarter 2024 revenue totaled $28.8 million, representing year over year growth of 5% on a reported basis and 5% on a constant currency adjusted like-for-like basisTotal Explore customer installations reached 121, with 14 installations during the first quarterTotal Signature Q100 placements reached 202, with 16 placements during the first quarterExplore revenue of $18.0 million accounted for 63% of total first quarter revenue, with Explore Kit revenue totaling $11.3 million, or 63% of t

      5/13/24 6:00:00 AM ET
      $OLK
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Report from the Annual General Meeting of Olink Holding AB (publ) on 19 April 2024

      UPPSALA, Sweden, April 19, 2024 (GLOBE NEWSWIRE) -- At the Annual General Meeting (the "AGM") of Olink Holding AB (publ), reg. no 559189-7755, (the "Company"), on 19 April 2024 the AGM adopted, inter alia, the following resolutions. For more detailed information regarding the contents of the resolutions, please refer to the notice to the AGM and the complete proposals, which have previously been published and are available on the Company's website, www.olink.com. Adoption of the balance sheet and income statement, disposition regarding the Company's results and discharge from liabilityThe AGM adopted the Company's income statement and balance sheet and the consolidated income statement an

      4/19/24 4:05:00 PM ET
      $OLK
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Olink reports fourth quarter and full year 2023 financial results

      UPPSALA, Sweden, March 25, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) ("Olink") (NASDAQ:OLK) today announced its unaudited financial results for the fourth quarter ended December 31, 2023. Highlights Fourth quarter 2023 revenue totaled $68.6 million, representing year over year growth of 18% on a reported basis and 17% on a constant currency adjusted like-for-like basisFull year revenue 2023 revenue totaled $169.6 million, achieving year over year growth of 21% on a reported basis and 21% on a constant currency adjusted like-for-like basisTotal Explore customer installations reached 107, with 20 installations during the fourth quarterTotal Signature Q100 placements reached 186, wit

      3/25/24 8:00:00 AM ET
      $OLK
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $OLK
    Leadership Updates

    Live Leadership Updates

    See more
    • Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company's Proposed Merger with Standard BioTools

      Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4

      12/12/23 5:31:00 PM ET
      $EXAS
      $ILMN
      $LAB
      $ME
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cellarity Appoints Dr. Gregory J. Moore to Board of Directors

      Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the appointment of Gregory J. Moore, M.D., Ph.D., to the Company's Board of Directors. As the former Corporate Vice President for Microsoft, leading global health and life sciences, Dr. Moore brings extensive experience and expertise in integrating R&D, AI and machine learning, and cloud and data technologies to positively transform companies within the health and life sciences ecosystem. "Greg is an industry leader, driving technology and life sciences innovation at the intersection of medical and large-scale computation," said Stephen Berenson, Chairman of Cellar

      6/6/23 8:00:00 AM ET
      $DNLI
      $DVA
      $EVLO
      $FHTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Misc Health and Biotechnology Services
      Biotechnology: Pharmaceutical Preparations
    • Bruno Rossi joins Olink as Chief Commercial Officer

      UPPSALA, Sweden, March 21, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) ("Olink") (NASDAQ:OLK) today announced the appointment of life sciences industry veteran Bruno Rossi to the role of Chief Commercial Officer (CCO), effective immediately. Mr. Rossi will lead the Company's global commercial organization including Sales, Marketing and Sales Operations. He will report to Carl Raimond, President of Olink. "I am delighted to welcome Bruno to the Olink organization, and look forward to the value his considerable industry experience will add to our rapidly growing company." said Carl Raimond, President of Olink. "Over the past two years, Olink has experienced remarkable growth. We have a

      3/21/23 8:00:00 AM ET
      $OLK
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $OLK
    SEC Filings

    See more
    • SEC Form 15F-12B filed by Olink Holding AB

      15F-12B - Olink Holding AB (publ) (0001835539) (Filer)

      7/22/24 5:19:56 PM ET
      $OLK
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 6-K filed by Olink Holding AB

      6-K - Olink Holding AB (publ) (0001835539) (Filer)

      7/22/24 8:30:04 AM ET
      $OLK
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 14D9/A filed by Olink Holding AB

      SC 14D9/A - Olink Holding AB (publ) (0001835539) (Subject)

      7/17/24 8:30:07 AM ET
      $OLK
      Biotechnology: Laboratory Analytical Instruments
      Industrials